Search - tctmd.com

Displaying 581 - 600 of 795

Sort: Relevancy | Date

Presentation TCT 2013

Mesh-Covered Stents Are Optimal Management Strategy for Thrombus!

Presenter: Dariusz Dudek

October 31, 2013

Presentation TCT 2013

FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients

Presenter: George Dangas

October 31, 2013

Presentation TCT 2013

Update on Device Therapy for STEMI: Stents and Thrombectomy/Embolic Protection

Presenter: Praveen Chandra

October 31, 2013

Presentation TCT 2013

Indigenous Stents: New Technologies and Clinical Data

Presenter: Sreenivas Kumar

October 31, 2013

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

Presentation TCT 2013

Case 4 : A Complex Bifurcation with Planned 2 Stents

Presenter: Alaide Chieffo

October 30, 2013

Presentation TCT 2013

Case #1: One or Two Stents? Long-term Results from Nordic Baltic I Changed My Strategy!

Presenter: Michael Maeng

October 30, 2013

Presentation TCT 2013

Case #11: In the Future Bifurcation Stents Will Disappear!

Presenter: Evald Christiansen

October 30, 2013

Presentation TCT 2013

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

Presenter: Fernando Alfonso

October 30, 2013

Presentation TCT 2013

New Stents

Presenter: Sotirios Tsimikas

October 30, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

Presenter: Ankit Garg

October 29, 2013

Presentation TCT 2013

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Presenter: Peter Smits

October 29, 2013

Presentation TCT 2013

Comparison of Polymer-Free BioFreedom™ Stents with Durable Polymer Taxus Liberté™ Stents: 4-Year Results from the BioFreedom First-In-Man Trial

Presenter: 208788|Ricardo Costa

October 29, 2013

Presentation TCT 2013

Use Of 4 French Systems For Treating Fem-Pop Lesions: Advantages And Disadvantages: Lessons From The 4EVER Trial Using Astron Pulsar Stents And No Closure Devices

Presenter: Koen Keirse

October 29, 2013

Presentation TCT 2013

TCT-50. Angiographic Predictor of 2-Year Stent Thrombosis in Patients Receiving Drug-eluting Stents: Insights from the ADAPT-DES Study

Presenter: Philippe Généreux

October 29, 2013

Presentation TCT 2013

TCT-16. Incidence, mechanisms and outcome of longitudinal stent deformation (LSD) associated with Element, Resolute, Biomatrix and Xience stents: angiographic and case-by-case...

Presenter: Samer Arnous

October 29, 2013

Presentation TCT 2013

TCT-12. Short Versus Long-Term Clinical Outcomes In A Randomised Comparison Of Zotarolimus- and Sirolimus-Eluting Coronary Stents

Presenter: Michael Maeng

October 29, 2013

Presentation TCT 2013

SORT-OUT VI: A Prospective, Randomized, All-Comers Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Coronary...

Presenter: Bent Raungaard

October 29, 2013

Advertisement

Mesh-Covered Stents Are Optimal Management Strategy for Thrombus!

FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients

Update on Device Therapy for STEMI: Stents and Thrombectomy/Embolic Protection

Indigenous Stents: New Technologies and Clinical Data

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Case 4 : A Complex Bifurcation with Planned 2 Stents

Case #1: One or Two Stents? Long-term Results from Nordic Baltic I Changed My Strategy!

Case #11: In the Future Bifurcation Stents Will Disappear!

RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

New Stents

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-18. Clinical and Procedural Predictors and Consequences of Stent Thrombosis Following Drug-eluting Stents for Acute Coronary Syndromes: Results From the ADAPT-DES Study

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Comparison of Polymer-Free BioFreedom™ Stents with Durable Polymer Taxus Liberté™ Stents: 4-Year Results from the BioFreedom First-In-Man Trial

Use Of 4 French Systems For Treating Fem-Pop Lesions: Advantages And Disadvantages: Lessons From The 4EVER Trial Using Astron Pulsar Stents And No Closure Devices

TCT-50. Angiographic Predictor of 2-Year Stent Thrombosis in Patients Receiving Drug-eluting Stents: Insights from the ADAPT-DES Study

TCT-16. Incidence, mechanisms and outcome of longitudinal stent deformation (LSD) associated with Element, Resolute, Biomatrix and Xience stents: angiographic and case-by-case...

TCT-12. Short Versus Long-Term Clinical Outcomes In A Randomised Comparison Of Zotarolimus- and Sirolimus-Eluting Coronary Stents

SORT-OUT VI: A Prospective, Randomized, All-Comers Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Coronary...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content